Johnson & Johnson announced from Titusville, New Jersey that it will present 24 abstracts at the 2026 Psych Congress Annual Meeting in New Orleans, scheduled for September 15‑19.
The abstracts span clinical data across the company's neuropsychiatry portfolio, featuring pivotal Phase 3 results for CAPLYTA (lumateperone) in bipolar mania, with additional data on bipolar depression, major depressive disorder and real‑world evidence on treatment patterns.
SPRAVATO (esketamine) nasal spray data will focus on depressive symptoms such as anhedonia, while seltorexant will be presented with Phase 3 results for major depressive disorder accompanied by insomnia.
The company also highlighted real‑world studies evaluating schizophrenia‑related hospitalizations in young dual‑eligible patients prior to initiation of long‑acting injectables.
Approved indications cited include CAPLYTA 42 mg for adjunctive therapy in major depressive disorder, schizophrenia and bipolar depressive episodes, and SPRAVATO for treatment‑resistant depression and acute suicidal ideation in major depressive disorder.
“By advancing clinical and real‑world evidence across our portfolio and pipeline, we aim to help move psychiatry forward so that clinicians can continue to make more informed decisions for the patients they serve,” said Jane Tiller, vice‑president and global head of neuroscience development at Johnson & Johnson.
At the time of the announcement, JNJ shares closed at $265.58, down 0.77 points or 0.29%.
